Abstract
A highly sensitive ultra-high pressure liquid chromatography (UHPLC-MS/MS) method for estimation of paclitaxel in rat plasma has been validated. The chromatographic separation was achieved using isocratic mobile phase, consisting of acetonitrile–2mM ammonium acetate (70:30 v/v; 0.25 mL min-1). Docetaxel was used as an internal standard and tert-butyl methyl ether (TBME) as organic solvent for the liquid-liquid extraction. The mass spectrometer was operated in synapt mass spectrometry mode via positive electrospray ionization using the transitions m/z 854.4 → 286.1for paclitaxel, and m/z 808.3→ 527.2 as a parent ion of docetaxel (IS). The mean extraction-efficiency of QC samples was 90%. The lower limit of quantification (LLOQ) was 1.0 ng/mL. This method covered a linearity range from 1- 5000 ng/ml, with the total run time of 3.0 min. The applicability of UHPLC-MS/MS method was demonstrated and successfully applied for pharmacokinetic profiling of paclitaxel in rat plasma after oral administration.
Keywords: Paclitaxel, docetaxel, liquid-liquid extraction, tert-butyl methyl ether, oral administration, pharmacokinetic study.
Graphical Abstract
Current Bioactive Compounds
Title:Pharmacokinetic Analysis of Taxane Through a Validated Ultra-High Performance Liquid Chromatography-Synapt Mass Spectrometry (UHPLC-MS/MS ESI-Q-TOF) Method
Volume: 12 Issue: 2
Author(s): Javed Ahmad, Niyaz Ahmad, Kanchan Kohli, Showkat R. Mir and Saima Amin
Affiliation:
Keywords: Paclitaxel, docetaxel, liquid-liquid extraction, tert-butyl methyl ether, oral administration, pharmacokinetic study.
Abstract: A highly sensitive ultra-high pressure liquid chromatography (UHPLC-MS/MS) method for estimation of paclitaxel in rat plasma has been validated. The chromatographic separation was achieved using isocratic mobile phase, consisting of acetonitrile–2mM ammonium acetate (70:30 v/v; 0.25 mL min-1). Docetaxel was used as an internal standard and tert-butyl methyl ether (TBME) as organic solvent for the liquid-liquid extraction. The mass spectrometer was operated in synapt mass spectrometry mode via positive electrospray ionization using the transitions m/z 854.4 → 286.1for paclitaxel, and m/z 808.3→ 527.2 as a parent ion of docetaxel (IS). The mean extraction-efficiency of QC samples was 90%. The lower limit of quantification (LLOQ) was 1.0 ng/mL. This method covered a linearity range from 1- 5000 ng/ml, with the total run time of 3.0 min. The applicability of UHPLC-MS/MS method was demonstrated and successfully applied for pharmacokinetic profiling of paclitaxel in rat plasma after oral administration.
Export Options
About this article
Cite this article as:
Ahmad Javed, Ahmad Niyaz, Kohli Kanchan, R. Mir Showkat and Amin Saima, Pharmacokinetic Analysis of Taxane Through a Validated Ultra-High Performance Liquid Chromatography-Synapt Mass Spectrometry (UHPLC-MS/MS ESI-Q-TOF) Method, Current Bioactive Compounds 2016; 12 (2) . https://dx.doi.org/10.2174/157340721202160504222440
DOI https://dx.doi.org/10.2174/157340721202160504222440 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer
Current Molecular Medicine Validation of Human Clinical Genetic Tests
Mini-Reviews in Medicinal Chemistry Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry FbD Supported Development and In Vitro Evaluation of Carbomer based Resveratrol Loaded Topical Antipsoriatic Nanoemulgel for its Targeted Skin Delivery
Pharmaceutical Nanotechnology Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery HER2 in the Era of Molecular Medicine: A Review
Current Cancer Therapy Reviews Endocrine and Antineoplastic Actions of Growth Hormone-Releasing Hormone Antagonists
Current Medicinal Chemistry Studies on Coumarins and Coumarin-Related Compounds to Determine their Therapeutic Role in the Treatment of Cancer
Current Pharmaceutical Design Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
Current Cancer Drug Targets Exploring the Synthesis and Anticancer Potential of L-Tyrosine-Platinum(II) Hybrid Molecules
Medicinal Chemistry Cucurbitacin B Enhances the Anticancer Effect of Imatinib Mesylate Through Inhibition of MMP-2 Expression in MCF-7 and SW480 Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry LPA and its Analogs-Attractive Tools for Elucidation of LPA Biology and Drug Development
Current Medicinal Chemistry The Adenine Nucleotide Translocase 2, a Mitochondrial Target for Anticancer Biotherapy
Current Drug Targets MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising
Current Pharmaceutical Design The Development of Future Research Strategies from Reviewing Antiemetic Trials for Chemotherapy Induced Emesis
Reviews on Recent Clinical Trials Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design